Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks? - a podcast by ReachMD

CME credits: 0.25

Valid until: 12-08-2021

Claim your CME credit at https://reachmd.com/programs/cme/it-time-change-your-treatment-strategy-type-2-diabetes-patients-cv-risks/11747/

Have you switched your at-risk diabetes patients to an SGLT2 inhibitor? Join Drs. Christopher Cannon and Sam Dagogo-Jack as they answer key practice questions on reducing cardiovascular risk and renal dysfunction in patients with type 2 diabetes. Patients with type 2 diabetes have two to three times the risk of developing heart failure, particularly class III and IV. SGLT2 inhibitors are changing the way we address type 2 diabetes management in patients with multiple risk factors by reducing obesity, preventing renal dysfunction, and improving heart failure, which reduces heart failure hospitalizations.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD